

**PolyCore Therapeutics LLC** is focused on developing treatments for dyskinesia and cognitive impairment associated with CNS disorders.

## MANAGEMENT

**Kelly Beck, MBA**  
Chief Executive Officer

**Sandhya Kortagere, Ph.D.**  
Co-Founder and  
Chief Scientific Officer

**Thais Sielecki, Ph.D.**  
Chief Operating Officer

## BOARD OF DIRECTORS

**Jim Harris, MBA**  
Co-Founder and  
Chairman of the Board

**Sandhya Kortagere, Ph.D.**  
Co-Founder and  
Chief Scientific Officer

**Kelly Beck, MBA**  
Chief Executive Officer

**Chris Cashman**  
Former Marinus Chairman & CEO

For more information, please contact:

Kelly Beck, CEO  
kelly.beck@polycoretherapeutics.com  
www.polycoretherapeutics.com

## COMPANY HIGHLIGHTS

- Only company developing novel G protein-biased signaling D3 receptor agonist
- PCT-3012 is a potential breakthrough treatment for Parkinson's disease
- Improves motor symptoms without development of tolerance, dyskinesia or impulsive behaviors; Improves cognition
- Composition of matter and method of treatment patents
- \$1.5M NIH grant awarded to advance PCT-3012 preclinical studies
- IND-enabling studies in progress. IND targeted for 2H2022
- Multi-billion-dollar market potential in Parkinson's disease with initial target market for patients experiencing motor symptoms and Levodopa-induced dyskinesia

Program	Indication	Discovery	Preclinical	Phase 1	Phase 2	Phase 3	Milestones
	Parkinson's Disease (L-Dopa Induced Dyskinesia)	▶					Complete pre-clinical studies and file IND by 2H2022
PCT-3012	ADHD	▶					
	Huntington's Disease	▶					

